Futura Medical PLC
LSE:FUM
Futura Medical PLC
Income from Continuing Operations
Futura Medical PLC
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Futura Medical PLC
LSE:FUM
|
Income from Continuing Operations
-ÂŁ3.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-3%
|
||
GlaxoSmithKline PLC
LSE:GSK
|
Income from Continuing Operations
ÂŁ4.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-1%
|
||
AstraZeneca PLC
LSE:AZN
|
Income from Continuing Operations
$6.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
25%
|
CAGR 10-Years
12%
|
||
Verona Pharma PLC
NASDAQ:VRNA
|
Income from Continuing Operations
-$153.7m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
||
Hikma Pharmaceuticals PLC
LSE:HIK
|
Income from Continuing Operations
$290m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
||
Dechra Pharmaceuticals PLC
LSE:DPH
|
Income from Continuing Operations
-ÂŁ27.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Futura Medical PLC
Glance View
Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.
See Also
What is Futura Medical PLC's Income from Continuing Operations?
Income from Continuing Operations
-3.8m
GBP
Based on the financial report for Jun 30, 2024, Futura Medical PLC's Income from Continuing Operations amounts to -3.8m GBP.
What is Futura Medical PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-3%
Over the last year, the Income from Continuing Operations growth was 27%. The average annual Income from Continuing Operations growth rates for Futura Medical PLC have been -9% over the past three years , 15% over the past five years , and -3% over the past ten years .